08.03.2023 • NewsBachemPeptidesOligonucleotides

Bachem Inks $531 Million Peptides Manufacturing Deal

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531 million – to supply large volumes of peptides following a joint development project. The identity of the customer has not been disclosed.

Manufacturing will mostly take place at Bachem’s new facility that is currently being built in Bubendorf, Switzerland, and due to open in 2024. The order covers a five-year period running from 2027 to 2031.

“Bachem is making a major contribution to supplying the pharmaceutical and biotechnology industries with complex active ingredients for medicines. I am pleased that with this new and important development and supply agreement, we can further diversify our portfolio of long-term customer projects,” said CEO Thomas Meier.

The agreement is the latest in a series of contracts secured since last September. In December, Bachem signed an order to deliver peptide volumes worth a minimum of 1 billion Swiss francs for the period 2025 to 2029.

© Bachem
© Bachem

Two first contracts were signed in September 2022, worth 25 million and 150 million Swiss francs for 2023 and 2024 respectively.

Last October, Bachem revealed it had purchased some land in Eiken, which will be its third site in Switzerland. The company is also expanding capacity in Vionnaz, Switzerland, in the US at Torrance and Vista in California, and at St. Helens in the UK.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Bachem

Hauptstr. 144
4416 Bubendorf
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.